SWM
ALNY icon

SHP Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

SHP Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.6K Buy
114
+5
+5% +$1.7K ﹤0.01% 562
2025
Q4 		$43.2K Buy
+109
New +$48.2K ﹤0.01% 506

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SHP Wealth Management's ALNY Position: Q1 2026 in Review

SHP Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 4.6% in Q1 2026, buying an estimated $1.7K and bringing the position to 114 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #562.

SHP Wealth Management first reported a position in ALNY in Q4 2025 and has held it in 2 quarters since. The position peaked at $43.2K in Q4 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • SHP Wealth Management held 114 shares of Alnylam Pharmaceuticals worth $37.6K as of Q1 2026.
  • SHP Wealth Management bought 5 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.7K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #562 holding.
  • SHP Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • SHP Wealth Management's Alnylam Pharmaceuticals position peaked at $43.2K in Q4 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.